— Know what they know.
Not Investment Advice

ATNM AMEX

Actinium Pharmaceuticals, Inc.
1W: -2.5% 1M: +17.0% 3M: +21.8% YTD: -14.6% 1Y: -26.9% 3Y: -81.1% 5Y: -87.9%
$1.17
+0.02 (+1.74%)
 
Weekly Expected Move ±12.6%
$1 $1 $1 $1 $1
AMEX · Healthcare · Biotechnology · Tech Score Neutral · Power 56 · $36.7M mcap · 31M float · 0.442% daily turnover · Short 37% of daily vol

Balance Sheet Trends

Total Assets
$52M -32.7% ▼
5Y CAGR: -4.9%
Total Liabilities
$44M -0.5% ▼
5Y CAGR: +54.0%
Shareholders Equity
$8M -76.1% ▼
5Y CAGR: -33.7%
Cash & Investments
$48M -34.2% ▼
5Y CAGR: -5.5%
Total Debt
$2M +7.7% ▲
5Y CAGR: +18.1%
Net Debt
-$46M +35.1% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$78M$109M$77M$73M$48M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$78M$109M$77M$73M$48M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$442K$396K$226K$357K$1M
Total Current Assets$80M$111M$78M$75M$49M
Property, Plant & Equip.$639K$3M$3M$2M$2M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$313K$324K$0
Other Non-Current Assets$0$302K$0$0$335K
Total Non-Current Assets$639K$3M$3M$2M$2M
Total Assets$80M$114M$81M$77M$52M
— Liabilities —
Accounts Payable$6M$10M$8M$8M$0
Short-Term Debt$0$0$541K$0$722K
Deferred Revenue$0$0$0$0$35M
Other Current Liabilities$998K$0$0$0-$28M
Total Current Liabilities$7M$11M$8M$8M$8M
Long-Term Debt$0$0$0$0$972K
Other Non-Current Liab.$0$35M$0$0$35M
Total Non-Current Liabilities$3K$37M$37M$36M$36M
Total Liabilities$7M$48M$45M$44M$44M
— Equity —
Common Stock$22K$26K$28K$31K$31K
Retained Earnings-$256M-$289M-$338M-$376M-$410M
Accumulated OCI-$0-$0$0$0-$20K
Total Stockholders Equity$74M$66M$36M$33M$8M
Total Liabilities & Equity$80M$114M$81M$77M$52M
— Key Metrics —
Total Debt$310K$3M$2M$2M$2M
Net Debt-$78M-$106M-$75M-$71M-$46M
Total Investments$0$0$313K$324K$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms